ArticlePloS one2019
The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 156 citations in OpenAlex.
- Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Pooled it
- Efficacy andAntimicrobial agents and chemotherapy · 2025Trial
- Trial
- Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Safety and immunogenicity of an adjuvantedHuman vaccines & immunotherapeutics · 2021Trial
- Extensively drug-resistant ESBL-producing enterobacterales and coexisting antimicrobial resistance genes are associated with mortality in critically ill patients with cancer.Scientific reports · 2026Article
- Comparative Effectiveness of Empiric Antibiotics for Uncomplicated Urinary Tract Infection in Postmenopausal Women.O&G open · 2026Article
- Personalized Antibiogram: A Novel Multitask Machine Learning Framework for Simultaneous Prediction of Antimicrobial Resistance Profile With Enhanced Detection of Carbapenem Resistance in Enterobacteriaceae.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Prevalence of multidrug-resistant uropathogens isolated from patients with urinary tract infections in a tertiary hospital in Ghana.BMC microbiology · 2026Article
- Engineered gut symbionts mediate cross-phylum antagonism to suppress uropathogenicbioRxiv : the preprint server for biology · 2026Article
- Population Pharmacokinetics of a Novel Oral Fosfomycin Prophylactic Scheme in the Plasma and Prostate of Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia.Clinical pharmacokinetics · 2026Article
- Article
- Comparative Analysis of ESBL Phenotypes and Antimicrobial Resistance inMicrobial drug resistance (Larchmont, N.Y.) · 2025Article
- Trends in UropathogenicOpen forum infectious diseases · 2025Article
- New Perspectives on Antimicrobial Agents: Pivmecillinam.Antimicrobial agents and chemotherapy · 2025Review
- Urinary tract infection in adults: gaps in current guidelines - opinions from an international multidisciplinary panel and relevance to clinical practice.BMC proceedings · 2025Article
- The Role of Stratified Cumulative Antibiograms in the (Choice of Appropriate Antibiotics in Urinary Tract Infection) Management of Urinary Tract Infections.Pathogens (Basel, Switzerland) · 2025Article
- Detection of Integrons inInternational journal of microbiology · 2025Article
- Genomic epidemiology of extended-spectrum beta-lactamase-producingMicrobial genomics · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) caused by Escherichia coli have been historically managed with oral antibiotics including the cephalosporins, fluoroquinolones and trimethoprim-sulfamethoxazole. The use of these agents is being compromised by the increase in extended spectrum β-lactamase (ESBL)-producing organisms, mostly caused by the emergence and clonal expansion of E. coli multilocus sequence typing (ST) 131. In addition, ESBL isolates show co-resistance to many of oral agents. Management of UTIs caused by ESBL and fluoroquinolone-resistant organisms is becoming increasingly challenging to treat outside of the hospital setting with clinicians having to resort to intravenous agents. The aim of this study was to assess the prevalence of ESBL phenotypes and genotypes among UTI isolates of E. coli collected in the US during 2017 as well as the impact of co-resistance to oral agents such as the fluoroquinolones and trimethoprim-sulfamethoxazole. The national prevalence of ESBL phenotypes of E. coli was 15.7% and was geographically distributed across all nine Census regions. Levofloxacin and trimethoprim-sulfamethoxazole-resistance rates were ≥ 24% among all isolates and this co-resistance phenotype was considerably higher among isolates showing an ESBL phenotype (≥ 59.2%) and carrying blaCTX-M-15 (≥ 69.5%). The agents with the highest potency against UTI isolates of E. coli, including ESBL isolates showing cross-resistance across oral agents, were the intravenous carbapenems. The results of this study indicate that new oral options with the spectrum and potency similar to the intravenous carbapenems would address a significant unmet need for the treatment of UTIs in an era of emergence and clonal expansion of ESBL isolates resistant to several classes of antimicrobial agents, including oral options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.